

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 619 370 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 94104804.3

(31) Int. Cl.⁵: **C12N 15/12, C07K 13/00,
A61K 37/02**

(22) Date of filing: 25.03.94

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(30) Priority: 26.03.93 US 40742

(43) Date of publication of application:
12.10.94 Bulletin 94/41

(54) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

(71) Applicant: **AMGEN INC.**
Amgen Center,
1840 Dehavilland Drive
Thousand Oaks, CA 91320-1789 (US)

(72) Inventor: **Pierce, Glenn F.**
645 Lynwood Street
Thousand Oaks, CA 91360 (US)
Inventor: **Housley, Regina M.**
1002 Calle Pecos
Thousand Oaks, CA 91360 (US)
Inventor: **Morris, Charles F.**
3393 Daniel Street
Newbury Park, CA 91320 (US)

(74) Representative: **Vossius, Volker, Dr. et al**
Dr. Volker Vossius
Patentanwaltskanzlei - Rechtsanwaltskanzlei
Holbeinstrasse 6
D-81679 München (DE)

(57) **Keratinocyte growth factor (KGF) for its use in method of therapeutic treatment for the human or animal body.**

(57) Based on extensive *in vivo* studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF *in vivo* enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.

EP 0 619 370 A1